The global Cell and Gene Therapy Third-Party Logistics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Type (Clinical, Commercial), By Product (Cell Therapies, Gene Therapies), By Temperature Range (Ambient Storage, Refrigerated Storage, Ultra-Low Temperature Storage, Cryogenic Storage), By Therapeutic Area (Oncology, Neurology, Cardiovascular Diseases, Ophthalmology, Infectious Diseases, Others), By End-User (Biopharmaceutical Companies, CDMOs/CMOs, Others).
The cell and gene therapy third-party logistics (3PL) market is on track for substantial growth by 2025, spurred by the rapid development and commercialization of advanced therapies for various genetic disorders, cancers, and other rare diseases. Cell and gene therapies require highly specialized logistics solutions due to the sensitive nature of the biologic products, which often need to be stored at specific temperatures and handled with extreme care during transportation. Third-party logistics providers offer services such as cold chain logistics, tracking and monitoring, and regulatory compliance, ensuring that these therapies reach patients in optimal condition. The growing demand for personalized medicine, coupled with the increasing adoption of cell and gene therapies by healthcare providers, is driving the need for specialized logistics services. The market is also supported by the expansion of clinical trials and the regulatory approvals for more cell and gene therapies globally. North America and Europe are key markets for 3PL services in the field of cell and gene therapy, but the market is also growing rapidly in Asia-Pacific, where emerging economies are investing heavily in advanced healthcare technologies and biotechnology research.
The market report analyses the leading companies in the industry including Arvato SE, Cardinal Health, Cencora Corp, DHL, EVERSANA, FedEx, Knipper Health, Kuehne + Nagel, McKesson Corp, United Parcel Service of America Inc, and others.
A significant trend in the cell and gene therapy third-party logistics market is the growing demand for specialized cold chain logistics. Cell and gene therapies often require strict temperature control during storage and transport to maintain their efficacy, as many of these therapies involve biological components that are sensitive to temperature fluctuations. As the number of cell and gene therapy products entering the market increases, logistics providers are investing in advanced packaging solutions, real-time temperature monitoring, and ultra-cold storage technologies to ensure the safe and efficient delivery of these high-value therapies.
The rapid expansion of cell and gene therapy products in clinical trials and the market is driving the demand for third-party logistics services that specialize in the unique requirements of these therapies. The complexity of cell and gene therapies ranging from personalized treatments to large-scale production processes necessitates logistics providers with expertise in handling biological materials. This growing pipeline of therapies, including treatments for genetic disorders, cancer, and rare diseases, requires efficient and compliant logistics solutions to ensure that therapies reach patients in optimal condition.
An exciting opportunity exists in the development of advanced tracking and compliance solutions tailored to the logistics of cell and gene therapies. Real-time tracking systems that monitor not only temperature but also location, humidity, and other environmental conditions can enhance transparency and reduce the risk of spoilage. Furthermore, the increasing regulatory requirements for cell and gene therapies, including adherence to Good Distribution Practices (GDP) and the need for thorough documentation, present a market opportunity for logistics providers to offer end-to-end, fully compliant solutions that meet the stringent needs of the industry.
The Cryogenic Storage segment is expected to dominate the Cell and Gene Therapy Third-Party Logistics market by 2025, driven by the essential requirement for ultra-low temperature storage in the preservation of biologics such as cell and gene therapies. Cryogenic storage is crucial for maintaining the stability and viability of sensitive therapeutic materials, particularly those involving viral vectors, stem cells, and other gene-modified treatments. The increasing demand for personalized medicine and advancements in gene therapies, combined with the complex logistics involved in storing and transporting these biologics, makes cryogenic storage the preferred method for ensuring product integrity. The significant growth in biopharmaceutical developments will continue to drive the adoption of cryogenic storage, cementing its position as the largest segment in this market.
The oncology segment is expected to be the fastest growing in the cell and gene therapy third-party logistics market through 2034, driven by the rapid advancements in cancer treatments and the increasing reliance on third-party logistics for the distribution of specialized therapies. Cell and gene therapies are emerging as breakthrough treatments for various cancers, offering targeted and personalized approaches that can significantly improve patient outcomes. As these therapies become more complex, the need for efficient and reliable logistics solutions grows, particularly in handling and transporting sensitive materials like gene-modified cells and viral vectors. Third-party logistics providers are becoming essential in ensuring the safe, timely, and compliant delivery of these therapies to healthcare facilities. With the oncology sector experiencing continuous growth in gene therapy treatments and clinical trials, the oncology segment will see the highest demand for specialized logistics services throughout the forecast period.
In China, the rapid growth of the healthcare sector and a focus on improving its biopharmaceutical capabilities are driving demand for cell and gene therapy third-party logistics (3PL) services. With the government’s heavy investment in healthcare infrastructure and the increase in clinical trials for gene therapies, the need for efficient and temperature-sensitive logistics solutions has never been more critical. The growing market for personalized medicine and the increase in regulatory approvals for gene therapies create a higher demand for reliable distribution networks. Additionally, China's expanding cold chain infrastructure and advancements in logistics technology contribute to the country becoming a significant player in the 3PL market for cell and gene therapies.
India’s healthcare market is undergoing a transformative shift with an increasing number of biotechnology startups and pharmaceutical companies focusing on cell and gene therapies. With a large pool of patients suffering from genetic disorders, India presents a substantial opportunity for gene therapies. The country’s expanding logistics sector, particularly in temperature-controlled transportation and storage, is supporting the growth of this market. Furthermore, India’s rapid adoption of digital technologies, including blockchain for supply chain management, is enhancing the traceability and efficiency of gene therapy logistics. The increasing demand for these therapies and the improving cold chain infrastructure are expected to propel India’s share in the global cell and gene therapy third-party logistics market.
In the United States, the cell and gene therapy third-party logistics market is experiencing significant growth due to a strong regulatory framework, extensive research, and development efforts in the biotech sector. The U.S. is a leader in clinical trials, with a high number of gene therapy approvals and applications, necessitating efficient 3PL services. With its advanced healthcare infrastructure and logistics expertise, the country is a hub for cold chain management, ensuring the safe transportation of sensitive biologic therapies. Additionally, partnerships between pharmaceutical companies and third-party logistics providers are enhancing the scalability and flexibility of logistics solutions, contributing to the robust growth of this market in the U.S.
Germany is a key player in the European cell and gene therapy third-party logistics market, with its highly developed pharmaceutical and biotechnology industries. The country's strong focus on medical innovation, coupled with its robust healthcare infrastructure, is driving demand for efficient logistics solutions. The European Union's regulations, particularly around the transportation and storage of gene therapies, have spurred the development of specialized logistics services in Germany. Furthermore, Germany’s advanced cold chain logistics and tracking technologies are ensuring the safe delivery of sensitive therapies. As more gene therapies enter clinical trials and receive regulatory approval, Germany's logistics capabilities will continue to be in high demand.
In France, the cell and gene therapy third-party logistics market is expanding as a result of significant investments in biotechnology research and development. France’s position as a leader in personalized medicine and its supportive regulatory environment are driving the demand for specialized logistics services. With several gene therapy trials underway and an increase in the number of therapies reaching the market, the need for efficient distribution networks is growing. France’s advanced infrastructure for cold chain logistics, coupled with an increasing focus on AI and automation in logistics, is contributing to the seamless transport of these sensitive therapies, positioning the country as a key player in the European 3PL market for gene therapies.
The Middle East is witnessing a surge in demand for cell and gene therapy third-party logistics services due to growing investments in healthcare and biotechnology, particularly in countries like the UAE and Saudi Arabia. The region’s increasing number of healthcare facilities, along with government initiatives to improve healthcare accessibility, is driving the demand for advanced logistics solutions. With the Middle East being a key hub for clinical trials and research, efficient logistics services are essential to ensure timely delivery and safety of gene therapies. Additionally, the growing adoption of digital technologies and the establishment of cold chain infrastructure are enabling the region to support the safe distribution of these advanced therapies, positioning it as a growing market in the global logistics landscape.
|
Parameter |
Details |
|
Market Size (2025) |
$12.3 Billion |
|
Market Size (2034) |
$32 Billion |
|
Market Growth Rate |
11.2% |
|
Segments |
By Type (Clinical, Commercial), By Product (Cell Therapies, Gene Therapies), By Temperature Range (Ambient Storage, Refrigerated Storage, Ultra-Low Temperature Storage, Cryogenic Storage), By Therapeutic Area (Oncology, Neurology, Cardiovascular Diseases, Ophthalmology, Infectious Diseases, Others), By End-User (Biopharmaceutical Companies, CDMOs/CMOs, Others) |
|
Study Period |
2019- 2024 and 2025-2034 |
|
Units |
Revenue (USD) |
|
Qualitative Analysis |
Porter’s Five Forces, SWOT Profile, Market Share, Scenario Forecasts, Market Ecosystem, Company Ranking, Market Dynamics, Industry Benchmarking |
|
Companies |
Arvato SE, Cardinal Health, Cencora Corp, DHL, EVERSANA, FedEx, Knipper Health, Kuehne + Nagel, McKesson Corp, United Parcel Service of America Inc |
|
Countries |
US, Canada, Mexico, Germany, France, Spain, Italy, UK, Russia, China, India, Japan, South Korea, Australia, South East Asia, Brazil, Argentina, Middle East, Africa |
By Type
Clinical
Commercial
By Product
Cell Therapies
Gene Therapies
By Temperature Range
Ambient Storage
Refrigerated Storage
Ultra-Low Temperature Storage
Cryogenic Storage
By Therapeutic Area
Oncology
Neurology
Cardiovascular Diseases
Ophthalmology
Infectious Diseases
Others
By End-User
Biopharmaceutical Companies
CDMOs/CMOs
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Arvato SE
Cardinal Health
Cencora Corp
DHL
EVERSANA
FedEx
Knipper Health
Kuehne + Nagel
McKesson Corp
United Parcel Service of America Inc
*- List Not Exhaustive
About USD Analytics
Table of Contents
List of Charts and Exhibits
List of Tables
1. Executive Summary
What’s New in 2025?
Top 10 Takeaways from the industry
Potential Opportunities for Industry Stakeholders
Strategic Imperatives
Company Market Positioning
Industry Benchmarking Matrix
2. Research Scope and Methodology
Market Definition
- Market Segments
- Companies Profiled
Research Methodology
- Bottom-Up Method
- Top-Down Method
- Data Triangulation
Forecast Methodology
- Data Sources
- USDA Proprietary Databases
- External Sources
- Primary Research and Interviews
Conversion Rates for USD
Abbreviations
3. Strategic Landscape: Key Insights and Implications
Spotlight: Key Strategies opted by Business Leaders
Competitive Landscape
Market Size ($ Million) and Share (%) by Company, 2024
SWOT Analysis
- Key Market Strengths
- Key Market Weaknesses
- Potential Opportunities
- Potential Threats
Porter’s Five Force Analysis
- Summary
- Bargaining Power of Buyers- Impact Analysis
- Bargaining Power of Suppliers- Impact Analysis
- Threat of new entrants- Impact Analysis
- Intensity of Competitive Rivalry- Impact Analysis
Macro-Environmental Analysis
- Economic forecasts by Country, 2010- 2035
- Population forecasts by Country, 2010- 2035
- Inflation Outlook by Country, 2010-2035
- Impact of Russia-Ukraine Conflict, Sluggish China Growth, US Developments
5. Growth Opportunity Analysis
Trends at a Glance
- What are the most noteworthy trends in the market
- Where should leaders pay attention?
- What industries are likely to be affected by the growth?
Market Dynamics
- Charting a path forward
- Growth Drivers
- Growth Barriers
Key Industry Stakeholders
- Suppliers
- Manufacturers and Service Providers
- Distribution Channels
- End-Users and Applications
- Regulators
- Investors, Traders, and R&D Institutes
Regulatory Landscape
6. Market Size Outlook to 2034
Global Cell and Gene Therapy Third-Party Logistics Market Size Forecast, USD Million, 2018- 2034
- Historic Market Size, 2018- 2024
- Forecast Market Size, 2024- 2034
Scenario Analysis
- Low Growth Scenario: Definition and Outlook to 2034
- Reference Case: Definition and Outlook to 2034
- High Growth Scenario: Definition and Outlook to 2034
Pricing Analysis and Outlook
- Cell and Gene Therapy Third-Party Logistics Average Price Forecast, 2021- 2034
- Key Factors Shaping the Pricing Patterns
7. Historical Cell and Gene Therapy Third-Party Logistics Market Size by Segments, 2018- 2024
Key Statistics, 2024
Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, USD Million, 2018- 2024
Growth Comparison (y-o-y) across Cell and Gene Therapy Third-Party Logistics Types, 2018- 2024
Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, USD Million, 2018- 2024
Growth Comparison (y-o-y) across Cell and Gene Therapy Third-Party Logistics Applications, 2018- 2024
8. Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Segments, 2024- 2034
By Type
Clinical
Commercial
By Product
Cell Therapies
Gene Therapies
By Temperature Range
Ambient Storage
Refrigerated Storage
Ultra-Low Temperature Storage
Cryogenic Storage
By Therapeutic Area
Oncology
Neurology
Cardiovascular Diseases
Ophthalmology
Infectious Diseases
Others
By End-User
Biopharmaceutical Companies
CDMOs/CMOs
Others
9. Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Region
North America
Key Market Dynamics
North America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, USD Million, 2021-2034
North America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, USD Million, 2021-2034
North America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Sales Channel, USD Million, 2021-2034
North America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Country, USD Million, 2021-2034
Europe
Key Market Dynamics
Europe Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, USD Million, 2021-2034
Europe Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, USD Million, 2021-2034
Europe Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Sales Channel, USD Million, 2021-2034
Europe Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Country, USD Million, 2021-2034
Asia Pacific
Key Market Dynamics
Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, USD Million, 2021-2034
Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, USD Million, 2021-2034
Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Sales Channel, USD Million, 2021-2034
Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Country, USD Million, 2021-2034
South America
Key Market Dynamics
South America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, USD Million, 2021-2034
South America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, USD Million, 2021-2034
South America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Sales Channel, USD Million, 2021-2034
South America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Country, USD Million, 2021-2034
Middle East and Africa
Key Market Dynamics
Middle East and Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, USD Million, 2021-2034
Middle East and Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, USD Million, 2021-2034
Middle East and Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Sales Channel, USD Million, 2021-2034
Middle East and Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Country, USD Million, 2021-2034
10. United States Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
United States Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
United States Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
United States Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
11. Canada Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Canada Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Canada Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Canada Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
12. Mexico Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Mexico Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Mexico Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Mexico Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
13. Germany Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Germany Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Germany Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Germany Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
14. France Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
France Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
France Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
France Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
15. United Kingdom Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
United Kingdom Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
United Kingdom Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
United Kingdom Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
16. Spain Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Spain Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Spain Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Spain Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
17. Italy Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Italy Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Italy Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Italy Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
18. Benelux Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Benelux Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Benelux Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Benelux Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
19. Nordic Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Nordic Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Nordic Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Nordic Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
20. Rest of Europe Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Europe Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Rest of Europe Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Rest of Europe Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
21. China Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
China Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
China Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
China Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
22. India Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
India Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
India Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
India Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
23. Japan Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Japan Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Japan Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Japan Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
24. South Korea Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
South Korea Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
South Korea Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
South Korea Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
25. Australia Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Australia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Australia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Australia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
26. South East Asia Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
South East Asia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
South East Asia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
South East Asia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
27. Rest of Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Rest of Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Rest of Asia Pacific Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
28. Brazil Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Brazil Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Brazil Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Brazil Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
29. Argentina Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Argentina Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Argentina Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Argentina Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
30. Rest of South America Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of South America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Rest of South America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Rest of South America Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
31. United Arab Emirates Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
United Arab Emirates Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
United Arab Emirates Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
United Arab Emirates Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
32. Saudi Arabia Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Saudi Arabia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Saudi Arabia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Saudi Arabia Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
33. Rest of Middle East Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Middle East Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Rest of Middle East Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Rest of Middle East Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
34. South Africa Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
South Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
South Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
South Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
35. Rest of Africa Cell and Gene Therapy Third-Party Logistics Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Type, 2021- 2034
Rest of Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by Application, 2021- 2034
Rest of Africa Cell and Gene Therapy Third-Party Logistics Market Size Outlook by End-User, 2021- 2034
36. Key Companies
Market Share Analysis
Arvato SE
Cardinal Health
Cencora Corp
DHL
EVERSANA
FedEx
Knipper Health
Kuehne + Nagel
McKesson Corp
United Parcel Service of America Inc
Company Benchmarking
Financial Analysis
37. Recent Market Developments
38. Appendix
Looking Ahead
Research Methodology
Legal Disclaimer
By Type
Clinical
Commercial
By Product
Cell Therapies
Gene Therapies
By Temperature Range
Ambient Storage
Refrigerated Storage
Ultra-Low Temperature Storage
Cryogenic Storage
By Therapeutic Area
Oncology
Neurology
Cardiovascular Diseases
Ophthalmology
Infectious Diseases
Others
By End-User
Biopharmaceutical Companies
CDMOs/CMOs
Others
The Global Cell and Gene Therapy Third-Party Logistics Market Size is estimated at $12.3 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 11.2% to reach $32 Billion by 2034.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Arvato SE, Cardinal Health, Cencora Corp, DHL, EVERSANA, FedEx, Knipper Health, Kuehne + Nagel, McKesson Corp, United Parcel Service of America Inc
Base Year- 2024; Estimated Year- 2025; Historic Period- 2019-2024; Forecast period- 2025 to 2034; Currency: Revenue (USD); Volume